Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Journal article

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

  • Bell R Faculty of Medicine, Deakin University, Geelong, Australia.
  • Brown J Clinical Trials Research Unit, University of Leeds, Leeds.
  • Parmar M Medical Research Council Clinical Trials Unit, London, UK.
  • Toi M Faculty of Medicine, Kyoto University, Kyoto, Japan.
  • Suter T Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.
  • Steger GG Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Pivot X Medical Oncology Service, University Hospital Jean Minjoz, Besançon, France.
  • Mackey J Medical Oncology, Cross Center Institute, Edmonton, Canada.
  • Jackisch C Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany.
  • Dent R Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
  • Hall P Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Xu N Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Morales L Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Provencher L Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec, Canada.
  • Hegg R Oncology Department, Perola Byington Hospital/FMUSP, São Paulo, Brazil.
  • Vanlemmens L Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
  • Kirsch A Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin, Germany.
  • Schneeweiss A Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
  • Masuda N Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka, Japan.
  • Overkamp F Oncologianova, Recklinghausen, Germany.
  • Cameron D Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, UK.
Show more…
  • 2016-12-21
Published in:
  • Annals of oncology : official journal of the European Society for Medical Oncology. - 2017
English Background
The purpose of this analysis was to assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC).


Methods
Patients eligible for the open-label randomized phase III BEATRICE trial had centrally confirmed triple-negative operable primary invasive breast cancer (pT1a-pT3). Investigators selected anthracycline- and/or taxane-based chemotherapy for each patient. After definitive surgery, patients were randomized 1:1 to receive ≥4 cycles of chemotherapy alone or with 1 year of bevacizumab (5 mg/kg/week equivalent). Stratification factors were nodal status, selected chemotherapy, hormone receptor status, and type of surgery. The primary end point was invasive disease-free survival (IDFS; previously reported). Secondary outcome measures included overall survival (OS) and safety.


Results
After 56 months' median follow-up, 293 of 2591 randomized patients had died. There was no statistically significant difference in OS between treatment arms in either the total population (hazard ratio 0.93, 95% confidence interval [CI] 0.74-1.17; P = 0.52) or pre-specified subgroups. The 5-year OS rate was 88% (95% CI 86-90%) in both treatment arms. Updated IDFS results were consistent with the primary IDFS analysis. Five-year IDFS rates were 77% (95% CI 75-79%) with chemotherapy alone versus 80% (95% CI 77-82%) with bevacizumab. From 18 months after first study dose to study end, new grade ≥3 adverse events occurred in 4.6% and 4.5% of patients in the two arms, respectively.


Conclusion
Final OS results showed no significant benefit from bevacizumab therapy for early TNBC. Late-onset toxicities were rare in both groups. Five-year OS and IDFS rates suggest that the prognosis for patients with TNBC is better than previously thought.


ClinicalTrials.gov
NCT00528567.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/185054
Statistics

Document views: 16 File downloads: